公开(公告)号：US20100254980A1

公开(公告)日：2010-10-07

申请号：US12740134

申请日：2008-10-31

申请人： Feng Cong ,  Shamina M. Rangwala ,  Seth Ettenberg ,  Sabine Guth

发明人： Feng Cong ,  Shamina M. Rangwala ,  Seth Ettenberg ,  Sabine Guth

IPC分类号： A61K39/395 ,  C07K16/18 ,  A61P3/10 ,  A61P25/28 ,  A61P19/10 ,  A61P3/04 ,  A61P19/02 ,  A61P35/00

CPC分类号： C07K16/2863 ,  C07K2317/55 ,  C07K2317/75 ,  C07K2317/76

摘要： The invention discloses LRP6 agonizing or antagonizing binding molecules (e.g., antibodies or a Fab fragments), and their use to facilitate or inhibit Wnt pathway signaling, respectively. Said LRP6 agonizing or antagonizing binding molecules can be used to e.g., diagnose, ameliorate the symptoms of, protect against, and treat Wnt signaling disorders associated with aberrantly low or aberrantly high levels of Wnt pathway signaling, respectively. Non-limiting examples of disorders which can be treated associated with aberrant upregulation of Wnt signaling is cancer (e.g., colon cancer). Non-limiting examples of disorders which can be diagnosed, protected against, and treated include cancers, bone disorders (e.g., osteoporosis and osteoarthritis), diabetes, neurodegenerative diseases such as Alzheimer's disease, and fibrotic disorders.

摘要翻译： 本发明公开了分别促进或抑制Wnt通路信号传导的LRP6激动或拮抗结合分子（例如，抗体或Fab片段）及其用途。 所述LRP6激动或拮抗结合分子可分别用于例如诊断，改善与异常低或异常高水平的Wnt通路信号传导相关的Wnt信号传导障碍的症状，保护和治疗。 可以与Wnt信号传导异常上调相关的病症的非限制性实例是癌症（例如结肠癌）。 可以诊断，保护和治疗的疾病的非限制性实例包括癌症，骨病（例如骨质疏松症和骨关节炎），糖尿病，神经变性疾病如阿尔茨海默病和纤维化病症。